<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization - Health AI Hub</title>
    <meta name="description" content="FRAGMENTA introduces an end-to-end framework for drug lead optimization, combining a novel generative model that uses dynamic Q-learning for joint fragmentation">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20510v2" target="_blank">2511.20510v2</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yuto Suzuki, Paul Awolade, Daniel V. LaBarbera, Farnoush Banaei-Kashani
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20510v2" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20510v2" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">FRAGMENTA introduces an end-to-end framework for drug lead optimization, combining a novel generative model that uses dynamic Q-learning for joint fragmentation and generation with an agentic AI system for expert-driven objective refinement. This approach addresses limitations of small datasets and slow model tuning, demonstrating superior performance in cancer drug discovery by identifying significantly more high-scoring molecules and achieving more effective tuning than traditional human-centric methods.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research significantly advances drug discovery by providing a more efficient and effective method for generating and optimizing drug leads, particularly in scenarios with limited training data, thereby accelerating the identification of promising therapeutic candidates for various diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI system, FRAGMENTA, applies generative AI and agentic tuning to optimize the process of generating novel drug lead molecules. It aims to accelerate drug discovery by automating the iterative feedback and refinement loop, collaborating with (or eventually replacing) medicinal chemists in tuning model objectives for identifying high-scoring drug candidates, particularly demonstrated in cancer drug discovery.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>FRAGMENTA addresses the critical challenge of molecule generation from small, class-specific datasets (often <100 training examples) in drug discovery.</li>
                    
                    <li>It features a novel generative model that reframes molecular fragmentation as a 'vocabulary selection' problem, using dynamic Q-learning to jointly optimize fragmentation and generation, enhancing diversity and identifying key structural fragments.</li>
                    
                    <li>The framework includes an agentic AI system designed to refine optimization objectives through conversational feedback from domain experts, aiming to remove AI engineers from the tuning loop.</li>
                    
                    <li>This agentic system progressively learns domain knowledge from medicinal chemists to automate model tuning and accurately capture expert intent for drug design.</li>
                    
                    <li>In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules compared to baseline generative models.</li>
                    
                    <li>A fully autonomous Agent-Agent tuning system within FRAGMENTA demonstrated superior performance over traditional Human-Human tuning, confirming the efficacy of agentic AI in objective refinement.</li>
                    
                    <li>The research highlights the potential for significantly accelerating drug lead optimization by making the process more efficient, autonomous, and effective at capturing expert intuition.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FRAGMENTA employs a two-pronged methodology: 1) a generative model that utilizes dynamic Q-learning to jointly optimize molecular fragmentation (redefined as 'vocabulary selection') and subsequent molecule generation; and 2) an agentic AI system that refines optimization objectives through conversational feedback from human domain experts, progressively learning and automating the model tuning process.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as traditional baselines in real-world cancer drug discovery experiments. Furthermore, the fully autonomous Agent-Agent tuning system outperformed conventional Human-Human tuning, demonstrating its superior efficacy in capturing expert intent for objective refinement.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>FRAGMENTA has the potential to dramatically accelerate the early stages of drug discovery by rapidly identifying and optimizing drug leads with high therapeutic potential, particularly for diseases like cancer. Its ability to work effectively with limited training data could be transformative for drug discovery programs targeting rare diseases or highly specific, underexplored biological targets, potentially leading to faster development of new and more effective treatments.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations specific to the FRAGMENTA framework itself, focusing instead on the limitations of prior methodologies that FRAGMENTA aims to overcome.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The framework's design implies future work on further automating and generalizing the agentic tuning process, with the ultimate goal of fully removing human AI engineers from the loop and progressively learning broader domain knowledge for completely autonomous objective refinement in drug lead optimization.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Pharmaceutical R&D</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Drug discovery</span>
                    
                    <span class="tag tag-keyword">molecule generation</span>
                    
                    <span class="tag tag-keyword">generative AI</span>
                    
                    <span class="tag tag-keyword">fragmentation</span>
                    
                    <span class="tag tag-keyword">Q-learning</span>
                    
                    <span class="tag tag-keyword">agentic AI</span>
                    
                    <span class="tag tag-keyword">lead optimization</span>
                    
                    <span class="tag tag-keyword">cancer drug discovery</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Molecule generation using generative AI is vital for drug discovery, yet class-specific datasets often contain fewer than 100 training examples. While fragment-based models handle limited data better than atom-based approaches, existing heuristic fragmentation limits diversity and misses key fragments. Additionally, model tuning typically requires slow, indirect collaboration between medicinal chemists and AI engineers. We introduce FRAGMENTA, an end-to-end framework for drug lead optimization comprising: 1) a novel generative model that reframes fragmentation as a "vocabulary selection" problem, using dynamic Q-learning to jointly optimize fragmentation and generation; and 2) an agentic AI system that refines objectives via conversational feedback from domain experts. This system removes the AI engineer from the loop and progressively learns domain knowledge to eventually automate tuning. In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in capturing expert intent.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>